ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ASND Ascendis Pharma AS

134.78
-1.20 (-0.88%)
最終更新日: 01:13:29
15分遅延
名称 銘柄コード 市場 種別
Ascendis Pharma AS ASND NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
-1.20 -0.88% 134.78 01:13:29
始値 安値 高値 終値 前日終値
135.00 134.78 137.32 135.98
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0305:01GLOBEAscendis Pharma Reports First Quarter 2024 Financial Results
2024/4/2605:46GLOBEAscendis Pharma to Report First Quarter 2024 Financial..
2024/4/2421:30GLOBEUnited Kingdom’s MHRA Approves YORVIPATH®..
2024/3/0801:31EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0611:39EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0522:14EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0522:04EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0521:37EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0505:17EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0505:07EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0504:54EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0504:36EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0422:30GLOBEAscendis Pharma to Participate in the Leerink Partners..
2024/3/0201:00EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0107:13EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2906:49EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2807:45EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2205:17EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1707:16EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1707:15EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1707:14EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1506:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/1501:40EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1423:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0806:15EDGAR2Form 20-F - Annual and transition report of foreign private..
2024/2/0806:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/0806:01GLOBEAscendis Pharma Reports Fourth Quarter and Full Year 2023..
2024/2/0722:30GLOBEAscendis Pharma to Participate in the Oppenheimer 34th..
2024/2/0106:15GLOBEAscendis Pharma to Report Full Year 2023 Financial Results..
2024/2/0106:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/0106:01GLOBEAscendis Pharma Launches 2nd TransCon™ Product: YORVIPATH®..
2024/1/2922:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/2922:30GLOBENew Company Eyconis Formed to Develop Ascendis Pharma..
2024/1/1106:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0822:20GLOBEVector Pharma FZCO Announce Exclusive Distribution Agreement..
2024/1/0820:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0820:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0807:45GLOBEAscendis Pharma Introduces Vision 2030
2024/1/0804:00PRNUSSpecialised Therapeutics signs exclusive agreement with..
2024/1/0220:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2906:15GLOBEAscendis Pharma to Participate in the 42nd Annual J.P...
2023/12/2022:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2022:30GLOBESignificant Health and Quality of Life Improvements Achieved..
2023/12/2006:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1922:30GLOBETransCon™ hGH (lonapegsomatropin) Achieved Statistically..
2023/12/1406:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1122:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1122:30GLOBEFDA Accepts for Review Resubmitted NDA for TransCon PTH..
2023/12/0804:53EDGAR2Form 144 - Report of proposed sale of securities
2023/12/0606:20EDGAR2Form 144 - Report of proposed sale of securities

最近閲覧した銘柄

Delayed Upgrade Clock